Suggested use

FIELD OF APPLICATION: Cigapan® is recommended as a biologically active food supplement - a source of calcium, phosphorus.


the content in a daily dose of dietary supplement

Content in the daily dose of dietary supplements to food;

(% from the recommended daily intake level);

From 3 to 7 years

7-11 years old

Over 12 years old


26,0 mg (2,9%)

52,0 mg (4,7%)

52,0-104,mg (4,3-8,6%)


12,0 mg (1,5%)

24,0 mg (2,2%)

24,0-48,0 mg (2-4%)

*- Guidelines МР -08  «Norms of physiological energy and food requirements


Daily allowance

dose of dietary supplement

% from the recommended

daily intake * for adults


104,0-208,0 mg



48,0-96,0 mg


* -ТР ТС 022/2011 «Food products in terms of their labeling»


  • has a general strengthening effect on the body;
  • helps to increase vitality and performance;
  • has a pronounced antioxidant activity;
  • provides an increase in adaptogenic resources;
  • helps to normalize metabolism;
  • helps to improve the functional state of the endocrine, cardiovascular, urogenital systems and the gastrointestinal tract.

Numerous scientific, preclinical, and clinical studies have shown that Cigapan® contributes to:

  • increase the immunobiological and defenses of the body;
  • normalization of the metabolic effect (metabolism);
  • regulation of redox processes, hematopoiesis, endocrine gland function;
  • restoring hormonal balance;
  • normalization of mineral metabolism, incl. with osteoporosis;
  • strengthening and developing musculoskeletal tissue, and accelerating its recovery from injuries and fractures;
  • rapid regeneration of damaged tissues (wounds and burns);
  • has a geroprotective effect (slows down the aging process);
  • improves fertility;
  • stimulates sexual function in adults;
  • has a positive effect on the functional state of the liver;
  • has a detoxifying effect (promotes the elimination of toxins, heavy metals and radionuclides from the body);
  • reduces the side effects of radiation and chemotherapy;
  • increases psycho-emotional stability;
  • increases physical activity and stamina;
  • accelerates the recovery of forces after intense work, heavy physical and mental stress;
  • contributes to the rapid recovery of body functions under the influence of extreme factors, prolonged stress;
  • accelerates rehabilitation processes;
  • increases the period of remission in chronic diseases;
  • reduces the risk of developing diseases.

Recommendations for use:

  • children from 3 to 7 years old, 1 tablet (200 mg) 1 time per day with meals;
  • children from 7 years old - 2 tablets (200 mg each) 1 time per day with meals;
  • children from 12 years old take 2 tablets (200 mg) or 1 capsule (400 mg) 1-2 times a day with meals;
  • Adults take 2 capsules (400 mg) 1-2 times daily with meals.
  • Duration of admission: 1-2 months. Repeated courses are recommended after 2-3 months.

The use of Cigapan® simultaneously with the main therapy can increase the effectiveness of treatment of various diseases, protect against side effects of drugs and reduce treatment time. Increases the period of remission in chronic diseases.

Contraindications: individual intolerance to the components. It is recommended to consult a doctor before use.

CigaPan® is non-toxic, antimutagenic, does not cause side effects. Assessment of the potential ability of Cigapan® to cause toxic effects and adverse long-term effects (mutagenic, etc.) showed the complete safety of its use.

Children's, adult, sports packaging differ only in packaging design, release form and dosage, the composition is the same.

Specialized, economical packaging is produced for athletes - 90 capsules of 400 mg each.



metabolic syndrome (with a high risk of cardiovascular disease and type 2 diabetes); type I and II diabetes mellitus; hypertension of 1-2 degrees with concomitant obesity (against the background of a hyponatrium, hypolipidemic, anti-atherosclerotic diet reduced in calorie content); ischemic heart disease (CHD); diffuse enlargement of the thyroid gland of I-II degree, hyperfunction, endocrine ophthalmopathy; hypofunction of the thyroid gland; chronic destructive-inflammatory diseases of the gastrointestinal tract (gastric ulcer and 12 duodenal ulcer, gastritis); hepatitis B and C; enterovirus infection; impaired functions of the genitourinary system (impotence, chronic prostatitis, testicular hypofunction, oligozoospermia, asthenozoospermia, impaired erection quality, decreased libido); tuberculosis, including when combined with type 2 diabetes mellitus; lymphogranulomatosis; during the period of clinical and hematological compensation in patients with thrombocytopenia (ITP); hemophilia and patients with intact blood coagulation system; osteoporosis, musculoskeletal injuries, including fractures; gunshot wounds; states associated with psychological and physical overload: in extreme conditions when performing combat missions by employees of special units, among athletes of the highest and highly qualified; neurological diseases accompanied by degenerative-dystrophic and painful manifestations; acute poisoning with psychopharmacological drugs, narcotic drugs, carbon monoxide; asthenic, weakened patients, as well as drug addicted patients as an aid to alleviate withdrawal symptoms, as well as in remission; persons who have been exposed to ionizing radiation by the nature of their activities or who live in areas contaminated by accidents; nursing mothers living in ecologically disadvantaged regions.

According to clinical trials at the Research Institute of Neurology of the Russian Academy of Medical Sciences, the State Research Center of Preventive Medicine of the Ministry of Health of the Russian Federation, the Research Institute of Nutrition of the Russian Academy of Medical Sciences, the All-Russian Research Institute of Physical Culture and Sports, the Federal Research Center for Medical Sexology and Sexopathology, the Research Institute of Psychiatry, the Medical Radiological Research Center of the Russian Academy of Medical Sciences, the Hematological Research Center of the Russian Academy of Medical Sciences, The Military Clinical Hospital of the Internal Troops of the Ministry of Internal Affairs of Russia, the Moscow Research Institute of Pediatrics and Pediatric Surgery of the Ministry of Health of the Russian Federation, the N.V. N.V. Sklifosovsky Research Institute of Tuberculosis, Clinic of the Russian Research Institute of Gerontology, FPPO MMA them. THEM. Sechenov, Scientific Center EFiS, Neurological Department of St. Petersburg. Clinical Hospital of the Russian Academy of Sciences, the Russian Research Center of Roentgenoradiology of the Ministry of Health of the Russian Federation, the Research Institute of Influenza of the Russian Academy of Medical Sciences, the Municipal Healthcare Institution "Volskaya Children's Hospital" of the Ministry of Health of the Russian Federation, the OMON GUVD of Moscow.


Bronchial asthma; dysfunctional disorders of the gastrointestinal tract, including grade 2-3 dysbiosis; vegetative-vascular dystonia of the vagotonic type; osteoporosis due to genetic reasons: hereditary disorders of phosphorus-potassium metabolism (rickets-like diseases), connective tissue diseases, osteopathies; atopic dermatitis; children with a nephrotic form of glomerulonephritis who received long-term therapy with prednisone; pathologies caused by living in radiation-contaminated areas; with microelementosis in children living in ecologically unfavorable regions.

Conducted at the Moscow Research Institute of Pediatrics and Pediatric Surgery of the Ministry of Health of the Russian Federation and the Municipal Health Institution "Volskaya Children's Hospital" of the Ministry of Health of the Russian Federation.

Release form: 200 mg tablets, 400 mg capsules, in a package of 30, 60, 90, 120 pieces.

Storage conditions: at a temperature not exceeding + 25C.

Shelf life: 3 years.

Terms of sale: Through the pharmacy chain and specialized departments of the distribution network.

Manufacturer (manufacturer): LLC "PLANET OF HEALTH", 249360, Kaluga region., p. Khvastovichi, st. 2nd Lesnaya, d.10, office 26

(production address: 249360, Kaluga Region, S. Khvastovichi, Lesnaya St., 6) RUSSIA, t. +7 (484) 539-12-62.

TU 9219-001-20739463-2015

SGR No. RU. dated 01/28/2016.